Oncolytics Biotech has been granted a new U.S. patent protecting its proprietary manufacturing process for pelareorep, an investigational cancer immunotherapy, extending protection until 2044. This patent ensures the company's ability to produce pelareorep at commercial scale and strengthens its intellectual property portfolio. A previously filed method-of-use patent could extend protection until 2046, with additional patent filings planned in 2026 to broaden pelareorep's IP coverage. These developments support Oncolytics' strategy to advance pelareorep toward registration and commercialization in multiple cancer indications.
Veea Inc. has announced the commercial release of VeeaONE, a full-stack AI infrastructure platform that integrates edge-to-cloud hardware and software. The platform supports VeeaWare middleware on NVIDIA Jetson and x86/Arm servers, enabling secure, l...
Virtuals Protocol has introduced customizable tokenized indexes on the Robinhood Chain, allowing users to combine multiple assets into a single token. This innovation enables users to create and manage their own asset baskets and earn fees when other...
US spot Bitcoin ETFs saw net inflows of $107.8 million on Wednesday, while Ethereum ETFs attracted $53.8 million, signaling renewed institutional interest in crypto funds. Since their launch in January 2024, Bitcoin ETFs have accumulated over $51 bil...
Kaia has signed a strategic partnership with Xilo Labs to integrate Mochi, an onchain asset management platform, into Kaia's ecosystem. This collaboration allows users to invest stablecoins into diversified portfolios backed by tokenized real-world a...
Bitcoin's price surged to nearly $65,000 following softer-than-expected U.S. inflation data for June, easing fears of Federal Reserve rate hikes. However, on-chain data reveals two main groups of investors—long-term holders who bought near last year'...
